As I wrap up my “Pharma is your Phriend” series, lets take a look at some more research.
This is a very interesting analysis of cancer vaccine trials using data mining from Open Access journal, Immunome Research.
The authors have taken advantage of there being quite a lot of publicly available information on clinical trials these days (yes, it is there, if you know where to look¹) to amass a whole host of information on cancer vaccine clinical trials for a type of analysis known as data mining.
There own summary of the results reads:
This application enables rapid extraction of information about institutions, diseases, clinical approaches, clinical trials dates, predominant cancer types in the trials, clinical opportunities and pharmaceutical market coverage. Presentation of results is facilitated by visualization tools that summarize the landscape of ongoing and completed cancer vaccine trials. Our summaries show the number of clinical vaccine trials per cancer type, over time, by phase, by lead sponsors, as well as trial activity relative to cancer type and survival data. We also have identified cancers that are neglected in the cancer vaccine field: bladder, liver, pancreatic, stomach, esophageal, and all of the low-incidence cancers.
Two cool things I learned from the paper were: Vaccines for cancers have been in development since the 1970s, and melanoma has been the cancer studied most for a vaccine, even though the first ones out to market have been for cervical cancer (expect melanoma vaccines in the next 1-5 years?).
But as we are looking to shift this discussion towards the pharmaceutical industry, let’s look at who runs clinical trials (Pop up: Figure 2a).
Read the rest of this entry »
Blah Blah Blah